Antimicrobial Agents Practice Questions

Q: Tetracycline is used in prophylaxis of which of the following diseases?

Leptospirosis. ***Leptospirosis (Correct Answer)*** - **Doxycycline**, a tetracycline antibiotic, is the **standard prophylactic agent** for **leptospirosis**, especially for individuals with high exposure risk (travelers to endemic areas, military personnel, occupational exposure). - **Prophylactic regimen**: 200 mg once weekly during exposure and for 2 weeks after last exposure. - It helps prevent the disease by inhibiting bacterial growth before infection becomes established. *Cholera (Incorrect)* - While tetracyclines like doxycycline can be used to **treat cholera** to reduce fluid loss and duration of diarrhea, they are **not used for prophylaxis** in healthy individuals. - Prophylaxis relies on **safe water and sanitation practices**, **oral cholera vaccine**, and proper food handling—not routine antibiotic administration. *Brucellosis (Incorrect)* - **Tetracyclines** (doxycycline) are essential for the **treatment** of **brucellosis**, typically in combination with rifampicin or streptomycin for 6 weeks, due to its intracellular nature and risk of relapse. - However, they are **not routinely used for prophylaxis** against brucellosis, even in high-risk individuals. *Meningitis (Incorrect)* - **Tetracyclines are not recommended for prophylaxis of bacterial meningitis**. - Prophylaxis for close contacts of meningococcal meningitis typically involves **rifampin**, **ceftriaxone**, or **ciprofloxacin**—not tetracyclines.

Q: Which of the following is not typically used as a first-line treatment for Helicobacter pylori infection?

Ofloxacin. ***Ofloxacin*** - **Ofloxacin** is a **fluoroquinolone antibiotic** and is generally reserved for **second-line** or **rescue therapies** for *H. pylori* eradication due to increasing resistance and the availability of more established first-line regimens. - While fluoroquinolones can be effective, they are not typically included in standard **triple or quadruple first-line therapies** for *H. pylori* due to concerns about wider antimicrobial resistance and potential side effects when other agents are available. *Clarithromycin* - **Clarithromycin** is a key antibiotic in many **first-line triple therapy regimens** for *H. pylori* eradication, often combined with a proton pump inhibitor and amoxicillin or metronidazole. - Its effectiveness can be limited by regional **clarithromycin resistance rates**, which may necessitate alternative regimens. *Amoxicillin* - **Amoxicillin** is a commonly used antibiotic in **first-line triple therapy** for *H. pylori*, typically combined with a proton pump inhibitor and clarithromycin. - It is generally well-tolerated and effective, particularly in areas with lower rates of amoxicillin resistance. *Metronidazole* - **Metronidazole** is an important component of several **first-line *H. pylori* eradication regimens**, including classic triple therapy (when amoxicillin is not used) and bismuth-based quadruple therapy. - Its use depends on local **metronidazole resistance patterns** and patient tolerance, as some individuals experience side effects like a metallic taste or nausea.

Q: A patient with a confirmed infection by ESBL-producing Klebsiella pneumoniae is being treated with ceftriaxone. What modification is needed in his antibiotic treatment?

Replace ceftriaxone with imipenem. ***Replace ceftriaxone with imipenem*** - **ESBL-producing organisms** (Extended-Spectrum Beta-Lactamase) are resistant to **third-generation cephalosporins** like ceftriaxone [1]. - **Carbapenems**, such as imipenem, are generally the drugs of choice for serious infections caused by ESBL-producing bacteria due to their broad spectrum and stability against ESBL enzymes. *Replace ceftriaxone with a fluoroquinolone* - While fluoroquinolones are broad-spectrum antibiotics, resistance in **Klebsiella pneumoniae** is increasing, and they are not reliably effective against ESBL-producing strains. - Using a fluoroquinolone for a confirmed ESBL infection without susceptibility data could lead to treatment failure and increased resistance. *Continue the same antibiotics at higher doses* - **Ceftriaxone** is a beta-lactam antibiotic that is destroyed by **ESBL enzymes**, rendering it ineffective regardless of the dose. - Increasing the dose of an ineffective antibiotic will not overcome the resistance mechanism and may lead to increased toxicity without clinical benefit. *Replace ceftriaxone with ceftazidime* - **Ceftazidime** is also a **third-generation cephalosporin** and is susceptible to degradation by ESBL enzymes. - Switching from one third-generation cephalosporin to another will not address the underlying **ESBL resistance mechanism**.

Q: Maximum sterilizing action is shown by which anti-TB drug?

Rifampicin. ***Rifampicin*** - Rifampicin has the **maximum sterilizing activity** among all anti-TB drugs, killing semi-dormant and intermittently metabolizing bacilli in various tissue environments. - Its sterilizing effect is crucial for **shortening treatment duration from 12-18 months to 6 months** and preventing relapses. - Rifampicin acts on persisters that other drugs cannot eliminate, making it the most important sterilizing drug in TB therapy. *Pyrazinamide* - Pyrazinamide has **unique sterilizing activity specifically in acidic environments** (pH < 5.5) within macrophages and caseous necrotic lesions. - While highly effective in acidic conditions where other drugs work poorly, its sterilizing action is environment-specific, not the maximum overall. - Its addition to regimens allows treatment shortening from 9 months to 6 months. *Streptomycin* - Streptomycin is an **aminoglycoside** with bactericidal action against actively dividing extracellular M. tuberculosis. - It does not penetrate cells well and has minimal activity against intracellular or dormant bacilli, thus limited sterilizing action. *INH* - Isoniazid (INH) is the most potent **early bactericidal drug** against rapidly multiplying tubercle bacilli. - While highly effective at reducing bacterial load initially, it has limited activity against dormant persisters and thus less sterilizing action compared to rifampicin.

Q: Which of the following drugs is a prodrug that, after oral administration, is converted to an active agent, penciclovir?

Famciclovir. ***Famciclovir*** - **Famciclovir** is an oral prodrug of **penciclovir**. After absorption, it undergoes first-pass metabolism to penciclovir, its active antiviral form. - **Penciclovir** is effective against **herpes simplex virus (HSV)** and **varicella-zoster virus (VZV)**, inhibiting viral DNA polymerase. *Acyclovir (active drug)* - **Acyclovir** is an active antiviral drug and is well-known for its use directly as an antiviral, not as a prodrug for penciclovir. - Although it is also converted to an active triphosphate form inside infected cells, its structure is distinct from penciclovir. *Ganciclovir (for CMV infections)* - **Ganciclovir** is an antiviral drug primarily used to treat and prevent **cytomegalovirus (CMV)** infections. - It is an active nucleoside analog itself, similar to acyclovir, and is not a prodrug for penciclovir. *Fomivirsen (used for CMV retinitis)* - **Fomivirsen** is an antisense oligonucleotide used specifically for the treatment of **CMV retinitis** in AIDS patients. - Its mechanism of action involves binding to CMV mRNA to inhibit viral protein synthesis, and it is unrelated to penciclovir.

Q: Which of the following drugs inhibits post-translational modification of viral proteins?

Indinavir. ***Indinavir*** - This drug is a **protease inhibitor** that specifically targets the **HIV protease** enzyme [1]. - By inhibiting protease, Indinavir prevents the cleavage of viral polyproteins into functional individual proteins, thereby inhibiting the **post-translational modification** necessary for viral maturation and infectivity [2]. *Enfuvirtide* - Enfuvirtide is a **fusion inhibitor** that prevents HIV from entering CD4+ T-cells by blocking the fusion of the viral envelope with the host cell membrane. - Its mechanism of action is upstream of protein synthesis and modification, directly impacting viral entry, not post-translational processing. *Lamivudine* - Lamivudine is a **nucleoside reverse transcriptase inhibitor (NRTI)** that acts as a chain terminator during reverse transcription. - It interferes with the conversion of viral RNA into DNA, affecting an earlier stage of the HIV life cycle, not post-translational modification. *Zalcitabine* - Similar to Lamivudine, Zalcitabine is also a **nucleoside reverse transcriptase inhibitor (NRTI)**. - It incorporates into the newly synthesized viral DNA strand, causing premature termination because it lacks a 3'-hydroxyl group, thereby inhibiting DNA synthesis rather than protein modification.

Q: Most important side effect of ethambutol is:

Retrobulbar neuritis. ***Retrobulbar neuritis*** - **Ethambutol** is known to cause **retrobulbar neuritis**, which presents as **decreased visual acuity**, **red-green color blindness**, and a **central scotoma** [1, 2]. - This side effect is typically **dose-dependent** [1] and can be reversible if detected early and the drug is discontinued. *Hepatotoxicity* - While other anti-tuberculosis drugs like **isoniazid** and **rifampin** are commonly associated with hepatotoxicity, it is **not the primary or most important side effect of ethambutol**. - Ethambutol's impact on the liver is generally minor compared to its ocular effects. *Renal toxicity* - **Renal toxicity** is **not a significant or common side effect** of ethambutol. - Patients with pre-existing renal impairment may require dose adjustments due to altered drug elimination, but the drug itself does not commonly induce renal damage. *Peripheral neuropathy* - **Peripheral neuropathy** is a well-known side effect of **isoniazid**, another anti-tuberculosis drug, particularly in patients with pre-existing risk factors or vitamin B6 deficiency. - It is **rarely associated with ethambutol** and is not considered its primary adverse effect.

Q: Resistance to zidovudine develops due to:

Mutation at reverse transcriptase. ***Mutation at reverse transcriptase*** - Zidovudine is a **nucleoside reverse transcriptase inhibitor (NRTI)** that acts by inhibiting **HIV reverse transcriptase**. - **Mutations in the reverse transcriptase gene** can alter the enzyme's structure, preventing zidovudine from binding effectively or allowing the enzyme to efficiently excise the incorporated zidovudine, thereby leading to drug resistance. *Increased efflux of the drug from inside the cell* - While efflux pumps can cause drug resistance in some contexts (e.g., cancer chemotherapy), they are **not the primary mechanism** of zidovudine resistance in HIV. - Zidovudine resistance is predominantly driven by **viral enzyme modifications**. *Increased metabolism of the drug* - Enhanced host metabolism of zidovudine would reduce its availability, but this is **not a primary mechanism** of virus-mediated resistance. - Viral resistance mechanisms typically involve alterations in the **target protein** (reverse transcriptase) or reduced drug activation. *Decreased zidovudine 5 triphosphate formation* - Zidovudine must be **phosphorylated intracellularly to its active triphosphate form** to inhibit reverse transcriptase. - While impaired phosphorylation could theoretically reduce drug efficacy, zidovudine resistance is predominantly linked to **reverse transcriptase mutations** rather than issues with host cell phosphorylation.

Question 1

Which of the following medications is a first-line antitubercular drug used routinely in children of all age groups without significant monitoring limitations?

Accepted Answer

Pyrazinamide

Answer

Ethambutol

Answer

Streptomycin

Answer

Combination of all first-line ATT agents

Question 2

Tetracycline is used in prophylaxis of which of the following diseases?

Accepted Answer

Leptospirosis

Answer

Meningitis

Answer

Brucellosis

Answer

Cholera

Question 3

Which of the following is not typically used as a first-line treatment for Helicobacter pylori infection?

Accepted Answer

Ofloxacin

Answer

Clarithromycin

Answer

Amoxicillin

Answer

Metronidazole

Question 4

A patient with a confirmed infection by ESBL-producing Klebsiella pneumoniae is being treated with ceftriaxone. What modification is needed in his antibiotic treatment?

Accepted Answer

Replace ceftriaxone with imipenem

Answer

Replace ceftriaxone with a fluoroquinolone

Answer

Continue the same antibiotics at higher doses

Answer

Replace ceftriaxone with ceftazidime

Question 5

Maximum sterilizing action is shown by which anti-TB drug?

Accepted Answer

Rifampicin

Answer

Pyrazinamide

Answer

Streptomycin

Answer

INH

Question 6

Which of the following drugs is a prodrug that, after oral administration, is converted to an active agent, penciclovir?

Accepted Answer

Famciclovir

Answer

Acyclovir

Answer

Ganciclovir

Answer

Fomivirsen

Question 7

Which of the following drugs inhibits post-translational modification of viral proteins?

Accepted Answer

Indinavir

Answer

Lamivudine

Answer

Zalcitabine

Answer

Enfuvirtide

Question 8

A child was admitted to the hospital with Haemophilus influenzae meningitis. Cefotaxime is preferred over ampicillin because...

Accepted Answer

Cefotaxime is more effective against beta-lactamase producing strains.

Answer

Cefotaxime is more active against H.influenzae with altered penicillin-binding proteins.

Answer

Cefotaxime is a bactericidal drug.

Answer

Cefotaxime has lower oral bioavailability than ampicillin.

Question 9

Most important side effect of ethambutol is:

Accepted Answer

Retrobulbar neuritis

Answer

Hepatotoxicity

Answer

Renal toxicity

Answer

Peripheral neuropathy

Question 10

Resistance to zidovudine develops due to:

Accepted Answer

Mutation at reverse transcriptase

Answer

Increased efflux of the drug from inside the cell

Answer

Increased metabolism of the drug

Answer

Decreased zidovudine 5'-triphosphate formation

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?